Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
NCT03628053 · Novartis Pharmaceuticals · PHASE3 · withdrawn · last registry update 2020-07-09 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies in this patient population.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-05-24Also stopped (terminated): ADC Therapeutics S.A., ADCT-402 (NCT02669264)
- 2021-01-25Phase 3 first posted: Gruppo Italiano Malattie EMatologiche dell'Adulto, Ponatinib + Blinatumomab + Chemotherapy + Imatinib (NCT04722848)
- 2020-11-23Results posted on the registry: Novartis Pharmaceuticals, CTL019 T-cells (NCT02228096)
- 2020-09-14Results posted on the registry: Amgen, Blinatumomab + Dexamthasone (NCT03476239)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
- 2020-07-13Results posted on the registry: Amgen, Blinatumomab + Dexamethasone (NCT02393859)
- 2020-03-13Phase 3 first posted: Mats Heyman, Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses (NCT04307576)
- 2020-01-10Results posted on the registry: Amgen, Blinatumomab (NCT02412306)
- 2019-09-26Results posted on the registry: ADC Therapeutics S.A., ADCT-402 (NCT02669264)
- 2019-09-18Phase 3 first posted: Novartis Pharmaceuticals, CTL019 (NCT04094311)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision